Use of contrast media in diagnostic imaging: medico-legal considerations

C. Pomara · N. Pascale · F. Maglietta · M. Neri · I. Riezzo · E. Turillazzi

Received: 30 December 2014 / Accepted: 30 April 2015 / Published online: 17 June 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract Contrast media (CM) are used in imaging techniques to enhance the differences between body tissues on images. The ideal contrast medium should achieve very high concentration in the tissues without producing any adverse effects. Unfortunately, this has not been possible so far and all CM have adverse effects. The increasing use of CM is likely to give rise to a wide range of pitfalls, including compliance with and appropriateness of indications for the use of CM themselves, the choice of the ‘best’ contrast agent, off-label use, evaluation of special populations of patients, and competence to tackle emergency scenarios following the administration of CM. Even more prominent, and potentially more important, is the issue of informed consent which brings with it a duty to inform patients awaiting the administration of CM with regard to the nature of the procedure, the existence of alternative procedures, the extent of the risks relating to the use of CM and, finally, the risks relating to refusal of the procedure. All these issues may give rise to concerns about liability for failure to offer adequate information to patients or to carefully evaluate and balance the potential risks and benefits of the procedure or, finally, for being unprepared in the event of adverse reactions to CM, especially when these are severe and life-threatening. Educational and training programmes for radiologists are likely to shape change in the medical liability environment in the coming years.

Keywords Contrast media · Adverse reaction · Informed consent · Off-label use · Medical liability

Introduction

Contrast media (CM) enhance the quality of images, revolutionizing the radiologist’s ability to differentiate soft-tissue densities. Ideally, CM should achieve very high concentration in the tissues without producing any adverse effects. Unfortunately this has not been possible so far and all CM have adverse effects [1].

In the last decades procedures employing CM have rapidly increased. Significant improvements in the composition of CM during the past few decades have made them safer and better tolerated. Nonetheless, risks associated with CM have not been eliminated: varying degrees of adverse reactions continue to occur, and, in some situations, their use is problematic [2–7]. The reported rates of severe reactions to CM are quite low; however they can quickly become life-threatening and lead to death [8–11]. Radiologists have been challenged in many ways by the issues arising from the increasingly widespread use of CM. The aim of this review is to define those medico-legal issues we believe to be most pertinent to the use of CM in diagnostic imaging as we know it today.

Informed consent

The basic concept of informed consent is familiar to radiologists [12, 13]; radiologists are aware that no diagnostic investigation can be performed without the patient’s valid consent and that the patient must be given adequate information and sufficient data to be able to make an informed decision about the examination. However, failure to obtain
proper informed consent is a frequent cause of lawsuits. A recent United States nationwide research showed that the commonest causes of medical malpractice suits against radiologists were diagnostic errors and procedural complications, followed by inadequate communication with either patient or referring physician [14]. Data coming from European countries confirmed that lack or invalidity of informed consent is highly problematic in radiological practice [15–17]. Interestingly, O’Dwyer et al. [17] reported that more than 50% of the radiologists interviewed were unhappy with their policies for obtaining informed consent.

Effective physician–patient communication is an enduring process. Consent to medical intervention infers a profound relationship between patient and physician which cannot be compressed into a short encounter. It is a process which implies the doctor’s duty to inform patients of the benefits and potential risks of the treatment options, to answer their questions openly and honestly, to help patients in their choice and, finally, to accept that choice [18].

Special scenarios and caveats regarding the practice of radiology and particularly the use of CM need to be discussed.

One key question is that the patient-radiologist relationship tends to be brief and episodic, so that radiologists are unlikely to have an established relationship with the patient [19], and may not feel comfortable discussing the risks and complications of their procedures with the patient [20]. Undoubtedly, time is a critical issue for radiologists in the informed consent process [21, 22]. In their survey on current European practice, O’Dwyer et al. [17] report that, despite the fact the appropriate time for obtaining informed consent is considered to be more than 24 h prior to the procedure, very often it is obtained on the same morning or immediately before the procedure itself. However, patients have to be provided with adequate time to consider the information they have received. Finally, also the time that radiologists spend with patients is critical in ensuring that patients are satisfactorily informed [23].

Another key point is the amount of information, especially with regard to risks, that should be given to patients; and in radiological practice the use of CM exacerbates the issue [24–26]. The appropriateness of the use of CM, any alternative procedure, the risks and benefits of not undergoing the proposed diagnostic or interventional procedure with CM have to be outlined in the informative process. On exploring patients’ attitude towards informed consent for CM, Hopper et al. [27] pointed out that most people desire to be informed before a contrast injection. It is generally argued that excessive and detailed information about the risks of the procedure may increase the levels of anxiety in a patient awaiting administration of CM. On the contrary, balanced communication about the risks seems to reduce anxiety levels [28–30]. In the ACR manual on CM [13] it is stated that ‘because of the documented low incidence of adverse events, intravenous injection of contrast media may be exempted from the need for informed consent, but this decision should be based on state law, institutional policy, and departmental policy’. Other authors seem to take the same view [31].

Contrarily, we believe that the low statistical frequency of complications, specifically those which are life-threatening, does not exempt radiologists from the duty to inform patients of these specific risks. Obtaining consent for all radiological CM procedures is an ethical duty, regardless of the nature of the agent used and the incidence and severity of the possible adverse events. A correct informative process is one in which physicians communicate the gist of the message to the patients, i.e., that there is some risk involved in the use of CM. Communicating the gist without referring to statistics, tailoring information to the patient’s needs and facilitating people’s understanding are essential elements of informed consent when radiologists are using contrast agents.

Finally, the form of informed consent (written or verbal) that is mainly based on state laws, and institutional and departmental policies. Some general considerations on the form of communication can be of interest. Efforts to improve information delivery and patient knowledge are widely reported in the literature as an important prerequisite for informed consent. There is wide agreement that a multimedia approach combining videos, verbal communication, audio tape, pamphlets, and interactive methods of communication may improve the patient’s comprehension and participation in the decision-making process [32]. The readability of informed consent forms is a critical issue [33] as many informative leaflets are written in such a way as to be incomprehensible to the average patient.

The above-mentioned criticisms arise particularly in emergencies where an inherent difficulty with obtaining adequate informed consent exists [34, 35].

Off-label use

The first point concerns the definition of off-label contrast medium (OLCM) which depends on the regulatory environment of different countries. In general terms, off-label use means use other than the originally tested and licenced indications, and the obtaining of licences depends on drug laws which may vary from country to country.

In the European normative framework, CM fall within the definition of medicinal product (EC Directive 2004/27/EC 31 March 2004): ‘Any substance or combination of substances which may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or
metabolic action, or to making a medical diagnosis’ [36, 37]. In the United States off-label use generally means that a medical product is not administered for the specific use approved by the food and drug administration (FDA) and listed in the drug-labelling information. To sum up, off-label use of a medical product is its prescription and use in a manner and for purposes other than those approved by competent authoritative agencies and national drug laws. Since these agencies regulate only the labelling of the medical products and do not regulate the practice of medicine, the off-label use of drugs and medical products is becoming increasingly common [38].

To fully understand the medico-legal implications of OLCM, the differences existing between CM and other drugs have to be taken into account. As outlined by Thomsen in his editorial, CM “are not designed to have therapeutic effects and they are administered in one dose, under medical supervision, and provide their effect under the principles of physics, not those of pharmacology” [39]. According to current regulations CM are officially approved for some specific uses and for body areas; their use in imaging the rest of the body is considered “off-label” [39]. For all these reasons, often the approved indications do not match the real clinical and diagnostic needs and in daily practice the off-label use of the CM is extremely common, mostly involving gadolinium-based contrast agents (GBCAs), especially in MR angiography, cardiac and paediatric applications [36, 40].

The most striking example is contrast-enhanced ultrasound (CEUS), particularly in the paediatric population, that is increasingly practised since it may reduce the use of ionizing radiations, and nowadays it is an established technique for many organs. In Europe, the use of CEUS is approved for a limited number of indications in adults [41]. Cardiac application of ultrasound contrast agent is approved in the United States, but it is not known when or if ultrasound contrast agents will be approved for non-cardiac applications there [42]. No-labelled use is approved in the paediatric population [43]. There is widespread use in Europe [44], and there are ongoing efforts by the Society for Paediatric Radiology and International Contrast Ultrasound Society to push for paediatric CEUS in the United States [45]. Therefore it may be expected that CEUS will be increasingly used throughout childhood [46].

Liability profiles may result from OLCM use since, despite widespread clinical practice, it is still formally outside the regulatory boundaries [37]. This incurs greater risks for the radiologist. It is known, for example, that with increasing off-label use, significant differences have not been observed in the incidence of severe adverse reactions between approved and unapproved use of CM [39]. Nevertheless, in the case of adverse reaction, especially if severe and life-threatening, the radiologist must demonstrate that the off-label use of that CM was fully supported by scientifically valid evidence and that there were no contraindications for the safety of the patient. This is a general requirement in off-label use of medical products which sharpens the need for strong scientific support for this practice. Making a clear distinction between CM off-label uses that are well supported by the best scientific evidence available and those that are not is the Gordian knot of the issue [47]. This concept is strongly supported by the statements of many scientific societies and regulatory bureaus. The FDA states that if a physician uses an off-label drug or medical device, he or she should base judgment on sound medical evidence and should maintain a record of the products used and their effects [48]. In a similar vein is the position of the Society of Interventional Radiology which supports the lawful use by a physician of a drug product for an unlabelled indication when such use is based on sound scientific evidence and/or sound medical opinion [49]. The second vital point, again with regard to the professional responsibility of the radiologist and possible requests for damages arising from the off-label use of the CM, is the information supplied to the patient prior to doing the exam. Since the radiologist uses a CM which the regulatory body has not stated is safe and effective for that specific use, we believe that he/she is obliged to provide exhaustive information to patients and obtain formal consent before using an OLCM. Conflicting conceptual positions arise around the thorny issue of informed consent in the off-label use of medical products. Some authors agree that it is not acceptable for a physician to neglect to tell patients of a medical product’s off-label status while some others have contended that off-label status is irrelevant to the actual medical risks posed [50–52]. While aware of the specific nature of the CM with regard to traditional medicines, we consider that the radiologist is still obliged to inform the patient of the off-label use of the CM, to explain the clinical and scientific reasons supporting it, to highlight the advantages in terms of effective diagnosis, to explain any alternative diagnoses and finally to obtain informed consent to the off-label use of the CM [40].

In conclusion, some key points can be drawn. If radiologists use a contrast agent for non-approved purposes, they are responsible for balancing the benefits and the potential negative effects of such use. They must also base its use on firm scientific rationale and on sound medical evidence when alternative labelled products are not of equally proven efficacy, and fully inform patients of the potential adverse effects of the product.

Finally, it should also be pointed out that it is the duty of radiologists to report any suspect adverse reaction associated with OLCM use to local/national authorities responsible for drug safety monitoring. Radiologists should be made aware that the reason for collecting information on OLCM use is to ensure the highest standard of patient
safety, possibly further to a review by ‘ad hoc’ local and national committees of incidents involving OLCM use and to subsequent appropriate actions.

Medical liability

The principles regulating medical liability differ from country to country and between common law and civil law systems, and malpractice in radiology varies across the globe [53]. Overall, the percentage of medical malpractice lawsuits involving radiologists has been estimated to range from 5 to 12 % [54, 55]. Diagnosis seems to be the major pitfall for radiologists [14]. In daily practice, around 3–5 % of radiological analyses contain errors [56–60]; errors in interventional procedures and adverse events occurring during a radiological examination take second place in this negative ranking [61].

The issue of medical liability and malpractice is not unique to radiologists; however, some key points have to be stressed, focusing particularly on the use of CM [2, 3, 62, 63].

Indication for the examination, and specifically the use of contrast media

Except for screening tests, radiologists generally receive the requests for examination from a referring physician. The decision of whether or not to conduct the examination and whether CM should be used is left to the radiologist [63]. Radiologists may fail to adequately check the appropriateness of the indication for the use of CM and to weigh up the diagnostic/therapeutic benefits and the possible risks. Existing guidelines may strongly assist the radiologist in making the most appropriate imaging decision for a specific patient [64, 65].

Investigation into medical history

Careful investigation into the patient’s medical history with special attention to eventual previous reaction to CM is critical. The radiologist who decides to use a contrast agent should investigate whether the patient has had a history of allergy and elicit from the patient any information regarding allergies through specific questions rather than simply relying on the patient, for the latter could overlook clinical significant details (i.e., previous life-threatening reaction, episodes of bronchospasm or asthma, hypotension or shock from an underlying illness, history of allergies, and other medical conditions, including possible renal impairment, heart failure, diabetes, hyperthyroidism, drug addiction, etc.) [65]. It is noteworthy that risk is increased sixfold by a history of adverse reaction, six to tenfold by asthma, and to a considerable extent by a history of allergic reactions to other drugs [66, 67].

Careful attention to special populations

Even more attention is required before administering CM to special populations.

Pregnant and breastfeeding women

Beyond the risks related to the exposure of the foetus to ionizing radiations and high magnetic fields, the administration of CM may be a further hazard for the foetuses and neonates [68]. CM cross the human placenta, thus entering the foetus. They can also be secreted into milk during lactation. Mutagenic effects have not been described after administration of gadolinium or iodinated CM [68–70]. However, the lack of adequate and well-controlled studies regarding these possible effects in humans has induced the ACR to recommend the use of iodinate-contrast media in pregnant women only when: ‘(1) the information requested cannot be acquired without contrast administration. (2) The information needed affects the care of the patient and foetus during the pregnancy. (3) The referring physician is of the opinion that it is not prudent to wait to obtain this information until after the patient is no longer pregnant’ [64]. The same caution is required when deciding to use GBCAs. Also, the updated version of ESUR guidelines [65] recommends that the use of iodine-based CM in pregnant women should be limited only to exceptional circumstances and that following their administration, thyroid function should be checked in the neonate during the first week. Regarding the use of gadolinium-based contrast agents, the revised guidelines recommend the administration of the smallest possible dose of the most stable GBCAs only when there is a very strong indication.

Both iodinate- and gadolinium-based CM are thought to be safe for mothers and children. However, full information about the mother with regard to the possibility of temporarily stopping lactation is suggested [13]. ESUR guidelines state that ‘breast feeding may be continued normally when iodine-based agents are given to the mother. Breast feeding should be avoided for 24 h after contrast medium if high risk agents are used’ [65]. A recent position paper of the Italian Society of Radiology, the Italian Society of Paediatrics, the Italian Society of Neonatology and the task force on breastfeeding, Italian Ministry of Health [71] states that ‘breastfeeding is safe for the nursing infant of any post-conceptional age after administration to the mother of all iodine-based contrast media and most gadolinium-based
contrast media. As a precaution, gadolinium-based agents considered at high risk of nephrogenic systemic fibrosis should be avoided in the breastfeeding woman. There is no need to discontinue breastfeeding for 12–48 h after the administration of contrast media and no use in expressing and discarding breast milk following the imaging’.

In conclusion, although the regulatory statements and clinical practice for the use of contrast media in pregnancy and lactation differ [70], caution is strongly advised and radiologists must be aware that the use of contrast media in pregnant women must be limited to cases when the benefits outweigh the potential risks. Accurate information and written informed consent to the procedure are strongly advised.

**Patients who take metformin**

They need special attention before the administration of CM since their use, and specifically iodine-based CM, may increase the risk of lactic acidosis patients taking metformin with known, borderline, or incipient renal dysfunction [72]. Management varies according to the recurrence and/or severity of renal impairment: no discontinuation of metformin nor creatinine control in patients with normal renal function and no comorbidities is required; discontinuation at the time of examination and for 48 h in patients with multiple comorbidities and apparently normal renal function, followed by the reassessment of renal function before restarting metformin is required. In patients with renal dysfunction, metformin should be suspended at the time of the contrast injection, and cautious follow-up of renal function should be performed until safe reinstitution of metformin nor creatinine control can be assured. It is not necessary to discontinue metformin prior to gadolinium-enhanced MR when the amount of gadolinium administered is in the usual dose range [64]. Taking the same view, ESUR guidelines advocate increased attention depending on the existence and severity of renal failure for iodinate CM. No special precautions are requested for GBCAs [65].

**Patients with previous renal insufficiency**

They are at greater risk of developing contrast-induced nephropathy (CIN) than patients whose function is normal. CIN is a well-described iatrogenic effect of the use of iodinate-contrast medium that occurs more frequently in patients with previous renal insufficiency [73]. These patients deserve special attention in the decision-making process leading to the use of CM. Radiologists must be fully informed and must use evidence-based protocols [74]. Statements from scientific associations provide specific recommendations on how to manage these patients [64, 65].

**Premedication**

Premedication is critical in possible liability scenarios linked to the use of CM. In some circumstances premedication is required. We refer to patients with previous reactions to CM for whom a pre-treatment regimen, including administration of corticosteroids with or without antihistamines or other medications, is thought to be safe. However, acute adverse reactions (breakthrough adverse reactions) are known to occur even when the patient is pre-medicated [75–77]. A recent review of the existing literature shows that in unselected patients, the usefulness of premedication is doubtful, and data supporting the use of premedication in patients with a history of allergic reactions are lacking [78]. Local institutional policies may exclude the use of CM in patients with prior moderate or severe reactions and in pre-medicated patients whose previous reactions were mild [77]; however, the Contrast Media Safety Committee of ESUR considers the use of premedication, although evidence of its effectiveness is limited in patients with previous moderate or severe acute reactions [65].

Several different premedication regimens have been proposed to reduce the frequency and/or severity of reactions to contrast media. The possible switch to other contrast agents, and the strict observation of the patients (20/30 min after the contrast medium injection, having drugs and equipment for resuscitation quickly and readily available) are also suggested as precautions for radiologists [79]. However, radiologists are reminded that they should be prepared to deal with the possible reactions [64, 65].

In conclusion, the take-home message is that radiologists must be wary of reactions in patients with a previous history of life-threatening reaction, bronchospasm or asthma, hypotension or shock from an underlying illness and allergies and be aware that premedication does not completely eliminate the risks of severe and life-threatening reactions in those patients. Staying alert and adequately prepared to administer resuscitation and supportive treatments are essential and cannot be replaced by premedication [76, 78]. The statement that ‘physicians who are dealing with these patients should not rely on the efficacy of premedication’ [78] must be kept in mind by radiologists when deciding whether or not to use CM in patients with prior reaction.

**Appropriateness and timeliness of adverse reaction management**

Finally, radiologists can be sued if the management of the adverse reaction induced by a contrast agent is not prompt and correct. Rapid identification of alarming, life-threatening symptoms and adequate therapeutic strategies are
recommended according to the kind and severity of the adverse reaction [80, 81]. However, knowledge of the management of acute contrast reactions is lacking among radiologists [82] and training and educational programmes are of paramount importance to help them to improve their performance in emergency scenarios following the administration of CM [82, 83].

Conclusions

The increasing use of CM is likely to give rise to a wide range of pitfalls, from compliance with and appropriateness of indications, to the choice of the ‘best’ contrast agent. Moreover, off-label use, evaluation of special populations of patients, and readiness to deal with emergency scenarios following the administration of CM are some of the most challenging issues for radiologists. Even more prominent, and potentially more important, is the issue of informed consent which implies a duty to inform patients awaiting the administration of CM of the nature of the procedure, the existence of alternative procedures, the extent of the risks related to their use and, finally, the risks of refusing the procedure.

All the above-mentioned issues may give rise to concerns about liability for failure to offer adequate information to patients or to carefully evaluate and balance the potential risks and benefits of the procedure or, finally, for being unprepared in the event of adverse reactions to CM, especially when severe and life-threatening. Educational and training programmes for radiologists are likely to shape change in the medical liability environment in the years to come.

Conflict of interest  None.

Ethical standards  This article does not contain any studies with human participants or animals performed by any of the authors.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Aspelin P, Bellin MF, Jakobsen JA, Webb JAW (2006) Classification and terminology. In: Thomsen HS (ed) Contrast media. Safety issues and ESUR guidelines. Springer, Berlin, pp 1–4
2. Bettman MA (2004) Frequently asked questions: iodinated contrast agents. Radiographics 24:S3–S10
3. Bui KL, Horner JD, Herts BR, Einstein DM (2007) Intravenous iodinated contrast agents: risks and problematic situations. Cleve Clin J Med 74(5):361–367
4. Namasivayam S, Kalra MK, Torres WE, Small WC (2006) Adverse reactions to intravenous iodinated contrast media: a primer for radiologists. Emerg Radiol 12(5):210–215
5. Hunt CH, Hartman RP, Hesley GK (2009) Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol 193(4):1124–1127
6. Tonolini M, Bianco R (2011) Acute adverse reactions to radiographic iodinated and gadolinium-based contrast media: incidence, risk factors and premedication: from published evidence to a practical approach. Clin Ter 162(6):591–594
7. Namasivayam S, Kalra MK, Torres WE, Small WC (2006) Adverse reactions to intravenous iodinated contrast media: an update. Curr Probl Diagn Radiol 35;164–169
8. Schopp JG, Iyer RS, Wang CL, Petscavage JM, Paladin AM, Bush WH, Dighe MK (2013) Allergic reactions to iodinated contrast media: premedication considerations for patients at risk. Emerg Radiol 20(4):299–306
9. Iyer RS, Schopp JG, Swanson JO, Thapa MM, Phillips GS (2013) Safety essentials: acute reactions to iodinated contrast media. Can Assoc Radiol J 64(3):193–199
10. Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC (2007) Frequency and severity of acute allergic-like reactions to gadolinium-containing IV contrast media in children and adults. AJR Am J Roentgenol 189:1533–1538
11. Wang CL, Cohan RH, Ellis JH, Caoli EM, Wang G, Francis IR (2008) Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions. AJR Am J Roentgenol 191(2):409–415
12. European Society of Radiology Code of Ethics, As of March, 2013 http://www.myesr.org/html/img/Pool/ESR_2012_ESRCodeofEthics-5.pdf
13. American College of Radiology http://www.acr.org/~media/ACR/Documents/PGTS/guidelines/Informed_Consent_Image_Guide.pdf Amended 2014
14. Wang JS, Baker SR, Patel R, Lak L, Castro A 3rd (2013) The causes of medical malpractice suits against radiologists in the United States. Radiology 266(2):548–554
15. Magnavita N, Fileen A, Mirk P, Magnavita G, Ricci S, Cotronaro AR (2013) Malpractice claims in interventional radiology: frequency, characteristics and protective measures. Radiol Med. 118(3):504–517
16. Mavroforou A, Giannoukas A, Mavrophoros D, Michalodimitrakis E (2003) Physicians’ liability in interventional radiology and endovascular therapy. Eur J Radiol 46(3):240–243
17. O’Dwyer HM, Lyon SM, Fotheringham T, Lee MJ (2003) Informed consent for interventional radiology procedures: a survey detailing current European practice. Cardiovasc Interv Radiol 26(5):428–433
18. Gillett G, Walker S (2012) The evolution of informed consent. J Law Med 19(4):673–677
19. Cardinal JS, Gunderman RB, Tarver RD (2011) Informing patients about risks and benefits of radiology examinations: a review article. J Am Coll Radiol 8(6):402–408
20. Reuter SR (1987) An overview of informed consent for radiologists. AJR Am J Roentgenol 148(1):219–227
21. Duda SH, Hölzer H (1995) The physician’s duty to inform in interventional radiological therapeutic procedures. Rofo 163(4):335–340
22. Neptune SM, Hopper KD, Houts PS, Hartzel JS, Ten Have TR. Loges RJ 3rd (1996) Take-home informed consent for intravenous contrast media: do patients learn more? Invest Radiol 31(2):109–113
23. Stickrath C, Druck J, Hensley N, Maddox TM, Richlie D (2012) Patient and health care provider discussions about the risks of medical imaging: not ready for prime time. Arch Intern Med 172(13):1037–1038
24. Lambe HA, Hopper KD, Matthews YL (1992) Use of informed consent for ionic and nonionic contrast media. Radiology 184(1):145–148

25. Hopper KD, Tyler HN Jr (1989) Informed consent for intravascular administration of contrast material: how much is enough? Radiology 171(2):509–514

26. Brazeau-Lamontagne L, Legault GA (1993) Consent: radiologists dilemma about contrast media. Can Assoc Radiol J 44(2):90–92

27. Hopper KD, Houts PS, Mc Caulsin MA, Matthews YL, Sefczek RJ (1992) Patients' attitudes toward informed consent for intravenous contrast media. Invest Radiol 27(5):362–366

28. Yacel A, Gecici O, Emul M, Oyar O, Gulsoy UK, Dayanir YO, Acar M, Degirmenci B, Haktanir A (2005) Effect of informed consent for intravascular contrast material on the level of anxiety: how much information should be given? Acta Radiol 46(7):701–707

29. Hopper KD, Houts PS, Ten Have TR, Matthews YL, Colon E, Haseman DB, Hartzel J (1994) The effect of informed consent on the level of anxiety in patients given iv contrast media. AJR Am J Roentgenol 162(3):531–535

30. Debray MP, Messin B, Bonville F, Laissy JP, Cinqualbre A, Schouman-Claesys E (1999) Patient information and iodized contrast media. J Radiol 80(5):437–440

31. Berlin L (2011) Informed consent for contrast media and gadolinium injections. AJR Am J Roentgenol 197(2):W359

32. Hopper KD, Zajdel M, Hulse SF, Yoanidis NR, Ten Have TR, Labuski MR, Houts PS, Bresniging CM, Hartman DS (1994) Interactive method of informing patients of the risks of intravenous contrast media. Radiology 192(1):67–71

33. Hopper KD, Lambe HA, Shir J (1993) Readability of informed consent forms for use with iodinated contrast media. Radiology 187(1):279–283

34. Cowan EA, Calderon Y, Gennis P, Macklin R, Ortiz C, Wall SP (2007) Spanish and English video-assisted informed consent for intravenous contrast administration in the emergency department: a randomized controlled trial. Ann Emerg Med 49(2):231–233

35. Iserson KV (2007) Is informed consent required for the administration of intravenous contrast and similar clinical procedures? Ann Emerg Med 49(2):231–233

36. Reimer P, Vossenich R (2008) Off-label use of contrast agents. Radiology 248(1):6–14

37. Raine JM (2006) Off-Label Use of Medicines – Legal Aspects. Springer, Berlin, pp 5–8

38. Wittich CM, Burkle CM, Lanier WL (2012) Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc 87(10):982–990

39. Thomsen HS (2013) For whom? Acta Radiol 54:473–475

40. Tamburrini O, Aprile I, Falcone C, Console D, Rotundo A (2011) Application of a second-generation US contrast agent in infants and children—a European questionnaire-based survey. Pediatr Radiol 42(12):1471–1480

41. Schreiber-Dietrich DG, Cui XW, Piscaglia F, Gilja OH, Dietrich CF (2014) Contrast enhanced ultrasound in pediatric patients: a real challenge. Z Gastroenterol 52(10):1178–1184

42. Walton SM, Schumock GT, Alexander GC, Meltizer D, Stafford RS (2010) Importance of distinguishing supported and unsupported off-label drug use. Arch Intern Med 170(7):657–658; author reply 658

43. Off-Label and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices—information sheet guidance for institutional review boards and clinical investigators U.S. food and drug administration. http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm. Accessed 20 Dec 2014

44. Society of interventional radiology executive council. SIR policy on off-label. http://www.sirweb.org/clinical/cpg/SIR_Off-label_use_statement11-18-07.pdf. Accessed 20 Dec 2014

45. Mithani Z (2012) Informed consent for off-label use of prescription medications. Virtual Mentor 14(7):576–581

46. Meadows WA, Hollowell BD (2008) Off-label drug use: an FDA regulatory term, not a negative implication of its medical use. Int J Impot Res 20(2):135–144

47. Vos F, Capron AM, Kraaf ME, Alexander GC, Kirschner KL (2013) Balancing burdens and benefits: ethical issues of off-label prescription pharmaceutical use. PM R 5(10):882–889

48. Cannavale A, Santoni M, Manacarella P, Passariello R, Arbarello P (2013) Malpractice in radiology: what should you worry about? Radiol Res Pract 2013:219259

49. Brenner RJ, Lucey LL, Smith JJ, Saunders R (1998) Radiology and medical malpractice claims: a report on the practice standards claims survey of the physician insurers Association of America and the American College of Radiology. AJR Am J Roentgenol 171(1):19–22

50. Berlin L (2003) Radiologic malpractice litigation: a view of the past, a gaze at the present, a glimpse of the future. AJR Am J Roentgenol 181(6):1481–1486

51. Rolferi R, Pescarinio L, Fileni A, Silvero R, Saccavini C, Visconti D, Morana G, Centonze M (2010) Clinical Risk Management in radiology. Part I: general background and types of error and their prevention. Radiol Med 115(7):1121–1146

52. Fileni A, Magnanivia N (2006) A 12-year follow-up study of malpractice claims against radiologists in Italy. Radiol Med 111(7):1009–1022

53. Fitzgerald R (2005) Radiological error: analysis, standard setting, targeted instruction and teamworking. Eur Radiol 15(8):1760–1767

54. Pescarinio L, Inches I (2006) Systematic approach to human error in radiology. Radiol Med 112(2):252–267

55. Raskin MM (2006) Survival strategies for radiology: some practical tips on how to reduce the risk of being sued and losing. J Am Coll Radiol 3(9):689–693

56. Olivetti L, Fileni A, De Stefano F, Cazzulani A, Battaglia G, Pescarinio L (2008) The legal implications of error in radiology. Radiol Med 113(4):599–608

57. Bush WH Jr, Albright DE, Sather JS (2005) Malpractice issues and contrast use. J Am Coll Radiol 2(4):344–347

58. Berllin L (2014) Medicolegal-malpractice and ethical issues in radiology. Liability for reaction to contrast media administration. AJR Am J Roentgenol 202(6):W597

59. ACR Appropriateness Criteria May 2014 http://www.acr.org/Quality-Safety/Appropriateness-Criteria. Accessed 2 Mar 2015
65. ESUR guidelines on Contrast Media [http://www.esur.org/guidelines/]. Accessed 2 Mar 2015
66. Palmer FJ (1988) The RACR survey of intravenous contrast media reactions. Final report. Australas Radiol 32(4):426–428
67. Katayama H, Yamaguchi K, Kozuka T, Takahashi T, Seez P, Matsuura K (1990) Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 175(3):621–628
68. Tremblay E, Thérasse E, Thomassin-Naggara I, Trop I (2012) Quality initiatives: guidelines for use of medical imaging during pregnancy and lactation. Radiographics 32(3):897–911
69. Kanal E, Barkovich AJ, Bell C, Borgstede JP, Bradley WG Jr, Froelich JW, Gilk T, Gimbel JR, Gosbee J, Kuhni-Kaminski E, Lester JW Jr, Nyenhuis J, Parag Y, Schaefer DJ, Sebek-Coumis EA, Weinreb J, Zaremba LA, Wilcox P, Lucey L, Sass N, ACR Blue Ribbon Panel on MR Safety (2007) ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 188(6):1447–1474
70. Webb JA, Thomsen HS (2013) Gadolinium contrast media during pregnancy and lactation. Acta Radiol 54(6):599–600
71. Cova MA, Stacul F, Quaranta R, Guastalla P, Salvatori G, Banderali G, Fonda C, David V, Gregori M, Zuppa AA, Davanzo R (2014) Radiological contrast media in the breastfeeding woman: a position paper of the Italian Society of Radiology (SIRM), the Italian Society of Paediatrics (SIP), the Italian Society of Neonato (SIN) and the task force on breastfeeding. Ministry of Health, Italy. Eur Radiol 24:2012–2022
72. Tonolini M (2012) Iodine-based radiographic contrast medium may precipitate metformin-associated lactic acidosis in diabetic patients. A case report, literature review and practical approach. Clin Ter 163(1):59–62
73. Moos SI, van Vemde DN, Stoker J, Bipat S (2013) Contrast induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: a meta-analysis. Eur J Radiol 82(9):e387–e399
74. Fishman EK, Reddan D (2008) What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography. Acta Radiol 49(3):310–320
75. Davenport MS, Cohan RH, Caoili EM, Ellis JH (2009) Repeat contrast medium reactions in pre-medicated patients: frequency and severity. Radiology 253(2):372–379
76. Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC (2008) Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication. AJR Am J Roentgenol 190(1):187–190
77. Jingu A, Fukuda J, Taketomi-Takahashi A, Tsushima Y (2014) Breakthrough reactions of iodinated and gadolinium contrast media after oral steroid premedication protocol. BMC Med Imaging 6(14):34
78. Tramèr MR, von Elm E, Loubeyre P, Hauser C (2006) Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. BMJ 333(7570):675
79. Webb JAW (2006) Prevention of acute reactions. In: Thomsen HS (ed) Contrast media. Safety issues and ESUR guidelines. Springer, Berlin, pp 11–19
80. Bush WH (2013) Treatment of acute contrast reactions. In: Arnold (Ed) Radiology Life Support (RAD-LS). London, pp 91–92
81. Collins MS, Hunt CH, Hartman RP (2009) Use of IV epi- nephrine for treatment of patients with contrast reactions: lessons learned from a 5-year experience. AJR Am J Roentgenol 192(2):455–461
82. Trout AT, Cohan RH, Ellis JH, Khalatbari S (2012) Teaching management of contrast reactions: does it work and how often do we need to refresh? Acad Radiol 19(4):498–504
83. Tubbs RJ, Murphy B, Mainiero MB, Shapiro M, Kobayashi L, Lindquist D, Smith JL, Siegel N (2009) High-fidelity medical simulation as an assessment tool for radiology residents acute contrast reaction management skills. J Am Coll Radiol 6(8):582–587